are registered for neovascular age-related macular degeneration. No formal safety study has been conducted for intravitreal bevacizumab
. These anti-vascular endothelial growth factor (anti-VEGF) drugs are being used on a large scale in daily practice for different ocular diseases. The objective of the present study was to systematically assess and compare the incidences of adverse events
A systematic search was conducted in April 2009 with no date restrictions in PubMed, Embase, Toxline, and the Cochrane library. We used the terms pegaptanib
, ranibizumab, intravitreal, and specific and general terms for adverse events
. Studies describing adverse events
after anti-VEGF injections and the official safety data were included.
Two hundred and seventy-eight articles were included, and the incidences of adverse events
were calculated separately for effect, safety, and specific side effect studies. The incidences of serious ocular and nonocular adverse events
were approximately below 1 per 100 injections for intravitreal bevacizumab
, intravitreal ranibizumab, and intravitreal pegaptanib
. Most mild ocular adverse events
were below 5 per 100 injections.
The reported rates of serious adverse events
were low after anti-VEGF injections. There is no sufficient evidence to conclude that there is a difference in incidences between the anti-VEGFs.